CRESCENT BIOPHARMA, INC. (CBIO)
↓ Download CSV- Sector Manufacturing
- Incorporated E9
- Fiscal year ends Dec 31
In fiscal 2025, CRESCENT BIOPHARMA, INC. reported revenue of $10.84M. The company ran a net loss, with a net margin of -1419.6%. It held $240.29M in total assets against $37.28M in total liabilities.
Key ratios (FY2025)
-1407.5%
Operating margin
-1419.6%
Net margin
-75.8%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.84M | — | — | — | — | — | — | — | — | — |
| Operating Income | -$152.63M | -$40.04M | -$39.28M | -$47.40M | -$63.45M | -$51.51M | -$61.39M | -$51.50M | -$33.93M | -$31.91M |
| Net Income | -$153.94M | -$37.88M | -$36.90M | -$46.69M | -$63.43M | -$51.03M | -$57.89M | -$48.27M | -$33.28M | -$31.81M |
| EPS (Diluted) | — | $-0.59 | $-0.58 | $-0.89 | $-1.23 | $-1.12 | $-1.34 | — | — | — |
| Total Assets | $240.29M | $35.62M | $45.32M | $51.81M | $94.35M | $142.83M | $167.97M | $214.84M | $128.58M | $42.39M |
| Total Liabilities | $37.28M | $47.10M | $6.90M | $8.88M | $12.74M | $14.61M | $13.77M | $9.37M | $8.88M | $7.09M |
| Shareholders' Equity | $203.01M | -$15.48M | $38.41M | $42.93M | $81.60M | $128.22M | $154.20M | $205.46M | $119.70M | $35.30M |
| Cash & Equivalents | $213.19M | $34.77M | $41.79M | $47.87M | $90.25M | $137.04M | $158.20M | $209.92M | $123.92M | $40.04M |
| Operating Cash Flow | -$71.53M | -$31.10M | -$34.88M | -$46.46M | -$57.49M | -$39.24M | -$51.98M | -$43.33M | -$29.77M | -$29.73M |
| Capital Expenditures | $919.0K | $10.0K | $21.4K | $84.2K | $14.9K | $68.5K | $144.9K | $125.6K | $294.1K | $704.2K |
| Shares Outstanding | 27.56M | 1.02M | 64.39M | 54.38M | 52.31M | 49.02M | 43.47M | 43.16M | 34.36M | 23.25M |